CA Patent

CA3253169A1 — Process for preparing tapinarof

Assigned to Dermavant Sciences GmbH · Expires 2025-10-27 · 1y expired

What this patent protects

There is a need for large-scale production of antibacterials, antioxidants and therapeutic compounds including anti-cancer compounds with low toxicity. The present invention provides processes for the preparation of 3, 5-Dihydroxy-4-isopropyl-trans-stilbene or a salt or solvate t…

USPTO Abstract

There is a need for large-scale production of antibacterials, antioxidants and therapeutic compounds including anti-cancer compounds with low toxicity. The present invention provides processes for the preparation of 3, 5-Dihydroxy-4-isopropyl-trans-stilbene or a salt or solvate thereof and intermediates used therein. The processes comprise decarboxylation, esterification, cyclization, halogenation and aromatization. In some embodiments the 3, 5-Dihydroxy-4-isopropyl-trans-stilbene is prepared from (E)-2-chloro- 2-isopropyl-5-styrylcyclohexane-l,3-dione. Also disclosed are crystal forms of 3, 5- Dihydroxy-4-isopropyl-trans-stilbene or a salt or solvate thereof and pharmaceutical compositions comprising same. The compounds and processes of the present invention can be manufactured on a larger scale, including with high-yielding synthesis, and have low toxicity.

Drugs covered by this patent

Patent Metadata

Patent number
CA3253169A1
Jurisdiction
CA
Classification
Expires
2025-10-27
Drug substance claim
No
Drug product claim
No
Assignee
Dermavant Sciences GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.